BridgeBio Oncology Therapeutics, Inc. (Bbot) announced that its innovative therapy Bbo-11818, for adult patients with advanced KRAS-mutated pancreatic ductal adenocarcinoma, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).

This designation will accelerate the development and review process of the candidate drug, bringing new treatment hope to patient groups with urgent unmet medical needs. As the most common type of pancreatic cancer, KRAS-mutant pancreatic ductal adenocarcinoma has long lacked effective targeted therapy options. Obtaining Fast Track designation not only demonstrates the therapeutic potential Bbo-11818 has shown in early research, but also means the drug can benefit from more frequent communication with the FDA during subsequent clinical trials, potentially expediting its progress to the marketing application stage.